Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.

Company Overview and News

Reata Receives Orphan Drug Designation from the European Commission for Omaveloxolone for the Treatment of Friedreich’s Ataxia

2018-07-10 globenewswire
IRVING, Texas, July 10, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced that the European Commission has granted orphan drug designation for omaveloxolone for the treatment of Friedreich’s ataxia (FA), based on the positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA).

Your Daily Pharma Scoop: Reata Begins New Trial, CytoDyn Amends Protocol, Argenx Reports Positive Data

2018-06-22 seekingalpha
Reata Pharmaceuticals (NASDAQ:RETA) begins Phase 1 clinical trial to evaluate the safety and pharmacokinetics of RTA 1701. RTA 1701 is one of a series of highly selective and orally bioavailable allosteric inhibitors of RORyt. The series has the potential to treat a wide range of autoimmune and inflammatory disorders. RORγt is the master transcription factor controlling the differentiation of naïve CD4+ precursor cells into Th17 cells.

Reata Announces Initiation of a Phase 1 Trial of RTA 1701, a Selective, Oral Allosteric Inhibitor of RORγt

2018-06-20 globenewswire
IRVING, Texas, June 20, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced the initiation of a Phase 1 clinical trial of Reata’s RTA 1701, a highly selective and orally bioavailable allosteric RORγt inhibitor. This Phase 1, first-in-human study is evaluating the safety and pharmacokinetics of RTA 1701 in healthy volunteers and assessing ex vivo suppression of IL-17A secretion.

Reata Pharma: This TPT Watchlist Stock Is Doing Pretty Well

2018-06-18 seekingalpha
We put Reata Pharmaceuticals (RETA) on our buylist for Total Pharma Tracker members on March 28, when it was trading at $20. In the last 3 months, it has exactly doubled.

Reata Pharmaceuticals, Inc. Secures $125 Million Term Loan Facility

2018-06-14 globenewswire
IRVING, Texas, June 14, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company, today announced that it entered into an amended and restated loan and security agreement with Oxford Finance LLC and Silicon Valley Bank, which increased the Company’s term loan facility from $45 million to $125 million. Proceeds from the loan will be utilized primarily to support Reata’s multiple Phase 2 and 3 clinical trial programs for bardoxolone methyl and omaveloxolone.

Reata Announces That Kyowa Hakko Kirin Initiated Ayame, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of Diabetic Kidney Disease

2018-06-04 globenewswire
IRVING, Texas, June 04, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced that its licensee, Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin), has initiated a Phase 3 clinical study, AYAME, to assess the efficacy and safety of bardoxolone methyl (bardoxolone) for the treatment of diabetic kidney disease in Japan.

Reata Selected to Present Early-Stage Programs at the BIO International Convention

2018-06-01 globenewswire
IRVING, Texas, June 01, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced that Chief Development Officer, Keith Ward, Ph.D., will present at the Annual BIO International Convention on Wednesday, June 6, 2018, at 1:00 p.m. ET in Boston, MA. The BIO International Convention is a premier partnering-focused event for the biopharmaceutical industry, and Reata’s selection as a presenting company highlights the strength of its early-stage assets, including RTA 901 and RTA 1701.

Reata Announces Orphan Drug Designation From the European Commission for Bardoxolone Methyl for the Treatment of Alport Syndrome

2018-05-31 globenewswire
IRVING, Texas, May 31, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced that the European Commission (EC) has granted orphan drug designation, based on the positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), for bardoxolone methyl (bardoxolone) for the treatment of Alport syndrome.

Can Reata Pharmaceuticals Continue To Rally?

2018-05-29 seekingalpha
We take a look at this rallying biopharma in the paragraphs below to determine if the stock can continue to rally.

Your Daily Pharma Scoop: Keryx, Reata And AstraZeneca Report Positive Results

2018-05-28 seekingalpha
We have followed Keryx (NASDAQ:KERX) for a while now, and we note the following developments in the last few months - sNDA approval for Auryxia in IDA patients in NDD-CKD, (iron deficiency anemia in non dialysis dependent patients with chronic kidney disease), withdrawal of guidance, EPS miss, poor sales figures vis-a-vis expectations, and finally the CEO departure. We also note that this $600mn market cap company has $141mn in cash, almost $94mn burn rate, and no other drug in its pipeline.

Bardoxolone Methyl Improved Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease and IgA Nephropathy in the Ongoing Phase 2 Phoenix Study

2018-05-25 globenewswire
IRVING, Texas, May 25, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (NASDAQ:RETA), a clinical-stage biopharmaceutical company, today announced that positive interim data from the autosomal dominant polycystic kidney disease (ADPKD) and IgA nephropathy cohorts of the ongoing, open-label, Phase 2 PHOENIX trial are being presented by Pablo E. Pergola, M.D., Ph.D., Research Director, Renal Associates, PA, San Antonio, at the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA) meeting in Copenhagen.

Reata Pharmaceuticals' (RETA) CEO Warren Huff on Q1 2018 Results - Earnings Call Transcript

2018-05-13 seekingalpha
Good day, ladies and gentlemen, and welcome to Reata Pharmaceuticals' Update on Development Programs Conference Call. [Operator Instructions]. An audio recording of today's webcast will be available shortly after the call today on Reata's website at in the Investors & News section.

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

1h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

Silicon Investor Message Boards

This table lists all message boards related to RETA / Reata Pharmaceuticals, Inc. on message board site Silicon Investor.

American Fire Retardant Corp Retail and Consumer Stocks
West 49 Inc.(WXX) skateboard and billabong retailer to11-17 PPMC - $4.50 stock says they may earn $5.50/share pretax!!
Pro Trading vs Retail Trading American Fire Retardant (AFRC)
Retail Sector Earnings Reports Electronic Retailing Systems International (ERSI Nasdaq)
Prime Retail (PRT) Retail investors and IPOu0027s
CUSIP: 75615P103